141 related articles for article (PubMed ID: 36468967)
21. A double-blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma.
Espinal-Perez LE; Moncada B; Castanedo-Cazares JP
Int J Dermatol; 2004 Aug; 43(8):604-7. PubMed ID: 15304189
[TBL] [Abstract][Full Text] [Related]
22. A clinical, prospective, randomized, double-blind trial comparing skin whitening complex with hydroquinone vs. placebo in the treatment of melasma.
Haddad AL; Matos LF; Brunstein F; Ferreira LM; Silva A; Costa D
Int J Dermatol; 2003 Feb; 42(2):153-6. PubMed ID: 12709008
[TBL] [Abstract][Full Text] [Related]
23. The treatment of melasma by silymarin cream.
Altaei T
BMC Dermatol; 2012 Oct; 12():18. PubMed ID: 23031632
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of tranexamic acid 5% cream vs hydroquinone 4% cream in treating melasma: A split-face comparative clinical, histopathological, and antera 3D camera study.
El-Husseiny R; Rakha N; Sallam M
Dermatol Ther; 2020 Nov; 33(6):e14240. PubMed ID: 32856757
[TBL] [Abstract][Full Text] [Related]
25. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser for the treatment of facial melasma in Asians.
Wattanakrai P; Mornchan R; Eimpunth S
Dermatol Surg; 2010; 36(1):76-87. PubMed ID: 20298254
[TBL] [Abstract][Full Text] [Related]
26. A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia.
Wang J; Fabi S; Robinson D; Bajaj S; Geronemus R; Bell M; Widgerow A
J Drugs Dermatol; 2023 Apr; 22(4):333-338. PubMed ID: 37026875
[TBL] [Abstract][Full Text] [Related]
27. Comparative study of therapeutic effects of 20% azelaic acid and hydroquinone 4% cream in the treatment of melasma.
Farshi S
J Cosmet Dermatol; 2011 Dec; 10(4):282-7. PubMed ID: 22151936
[TBL] [Abstract][Full Text] [Related]
28. Effective Tyrosinase Inhibition by Thiamidol Results in Significant Improvement of Mild to Moderate Melasma.
Arrowitz C; Schoelermann AM; Mann T; Jiang LI; Weber T; Kolbe L
J Invest Dermatol; 2019 Aug; 139(8):1691-1698.e6. PubMed ID: 30825454
[TBL] [Abstract][Full Text] [Related]
29. Fractional erbium:YAG laser (2940 nm) plus topical hydroquinone compared to intradermal tranexamic acid plus topical hydroquinone for the treatment of refractory melasma: a randomized controlled trial.
Mokhtari F; Bahrami B; Faghihi G; Asilian A; Iraji F
J Dermatolog Treat; 2022 Aug; 33(5):2475-2481. PubMed ID: 34387527
[TBL] [Abstract][Full Text] [Related]
30. Split-face comparison of hydroquinone 4% plus nitrogen plasma vs. hydroquinone 4% alone in the treatment of melasma.
Yousefi M; Hadian K; Babossalam S; Diab R; Akhlaghi M; Aghighi M; Abdollahimajd F; Shokri B
Lasers Med Sci; 2023 Apr; 38(1):113. PubMed ID: 37103690
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of dioic acid compared with hydroquinone in the treatment of melasma.
Tirado-Sánchez A; Santamaría-Román A; Ponce-Olivera RM
Int J Dermatol; 2009 Aug; 48(8):893-5. PubMed ID: 19659872
[TBL] [Abstract][Full Text] [Related]
32. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma.
Chan R; Park KC; Lee MH; Lee ES; Chang SE; Leow YH; Tay YK; Legarda-Montinola F; Tsai RY; Tsai TH; Shek S; Kerrouche N; Thomas G; Verallo-Rowell V
Br J Dermatol; 2008 Sep; 159(3):697-703. PubMed ID: 18616780
[TBL] [Abstract][Full Text] [Related]
33. Combined use of two formulations containing diacetyl boldine, TGF-β1 biomimetic oligopeptide-68 with other hypopigmenting/exfoliating agents and sunscreen provides effective and convenient treatment for facial melasma. Either is equal to or is better than 4% hydroquinone on normal skin.
Pratchyapurit WO
J Cosmet Dermatol; 2016 Jun; 15(2):131-44. PubMed ID: 26833454
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of Topical Silymarin Versus Low Fluence 1064-nm Q Switched Nd:YAG Laser in the Treatment of Melasma: A Comparative Randomized Trial.
Ibrahim SMA; Farag AS; Ali MS; El-Gendy WMAF
Lasers Surg Med; 2021 Dec; 53(10):1341-1347. PubMed ID: 34101206
[TBL] [Abstract][Full Text] [Related]
35. Investigator-Blinded, Single-Center Study to Evaluate the Efficacy and Tolerability of a 4% Hydroquinone Skin Care System Plus 0.02% Tretinoin Cream in Mild-to-Moderate Melasma and Photodamage.
Rendon M; Dryer L
J Drugs Dermatol; 2016 Apr; 15(4):466-75. PubMed ID: 27050702
[TBL] [Abstract][Full Text] [Related]
36. Is topical zinc effective in the treatment of melasma? A double-blind randomized comparative study.
Yousefi A; Khani Khoozani Z; Zakerzadeh Forooshani S; Omrani N; Moini AM; Eskandari Y
Dermatol Surg; 2014 Jan; 40(1):33-7. PubMed ID: 24237751
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of 4% hydroquinone combined with 10% glycolic acid, antioxidants, and sunscreen in the treatment of melasma.
Guevara IL; Pandya AG
Int J Dermatol; 2003 Dec; 42(12):966-72. PubMed ID: 14636195
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of Therapeutic Efficacy and Safety of Tranexamic Acid Local Infiltration in Combination with Topical 4% Hydroquinone Cream Compared to Topical 4% Hydroquinone Cream Alone in Patients with Melasma: A Split-Face Study.
Tehranchinia Z; Saghi B; Rahimi H
Dermatol Res Pract; 2018; 2018():8350317. PubMed ID: 30079087
[TBL] [Abstract][Full Text] [Related]
39. The efficacy in treatment of facial melasma with thulium 1927-nm fractional laser-assisted topical tranexamic acid delivery: a split-face, double-blind, randomized controlled pilot study.
Wanitphakdeedecha R; Sy-Alvarado F; Patthamalai P; Techapichetvanich T; Eimpunth S; Manuskiatti W
Lasers Med Sci; 2020 Dec; 35(9):2015-2021. PubMed ID: 32506227
[TBL] [Abstract][Full Text] [Related]
40. Clinical evaluation of efficacy, safety and tolerability of cysteamine 5% cream in comparison with modified Kligman's formula in subjects with epidermal melasma: A randomized, double-blind clinical trial study.
Karrabi M; David J; Sahebkar M
Skin Res Technol; 2021 Jan; 27(1):24-31. PubMed ID: 32585079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
